CN100528218C - Pharmaceutical composition, its preparation process and usage - Google Patents
Pharmaceutical composition, its preparation process and usage Download PDFInfo
- Publication number
- CN100528218C CN100528218C CNB2003101041689A CN200310104168A CN100528218C CN 100528218 C CN100528218 C CN 100528218C CN B2003101041689 A CNB2003101041689 A CN B2003101041689A CN 200310104168 A CN200310104168 A CN 200310104168A CN 100528218 C CN100528218 C CN 100528218C
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- pharmaceutical composition
- fructus
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 208000006454 hepatitis Diseases 0.000 claims abstract description 16
- 231100000283 hepatitis Toxicity 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims description 64
- 241001247783 Meconopsis Species 0.000 claims description 39
- 229940079593 drug Drugs 0.000 claims description 25
- 241000227129 Aconitum Species 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 13
- 239000000890 drug combination Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 11
- 208000002672 hepatitis B Diseases 0.000 claims description 10
- 235000012239 silicon dioxide Nutrition 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 8
- 241000726094 Aristolochia Species 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 241001046984 Meconopsis horridula Species 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000124209 Crocus sativus Species 0.000 abstract description 2
- 235000015655 Crocus sativus Nutrition 0.000 abstract description 2
- 235000019510 Long pepper Nutrition 0.000 abstract description 2
- 240000003455 Piper longum Species 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 240000007087 Apium graveolens Species 0.000 abstract 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 abstract 1
- 235000010591 Appio Nutrition 0.000 abstract 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 abstract 1
- 240000002943 Elettaria cardamomum Species 0.000 abstract 1
- 241001465251 Ephedra sinica Species 0.000 abstract 1
- 244000294611 Punica granatum Species 0.000 abstract 1
- 235000014360 Punica granatum Nutrition 0.000 abstract 1
- 244000061456 Solanum tuberosum Species 0.000 abstract 1
- 235000002595 Solanum tuberosum Nutrition 0.000 abstract 1
- BLUAFEHZUWYNDE-NNWCWBAJSA-N artemisinin Chemical compound C([C@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-NNWCWBAJSA-N 0.000 abstract 1
- 229960004191 artemisinin Drugs 0.000 abstract 1
- 235000005300 cardamomo Nutrition 0.000 abstract 1
- 235000013974 saffron Nutrition 0.000 abstract 1
- 239000004248 saffron Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 10
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 208000019838 Blood disease Diseases 0.000 description 4
- 206010023126 Jaundice Diseases 0.000 description 4
- 240000000103 Potentilla erecta Species 0.000 description 4
- 235000016551 Potentilla erecta Nutrition 0.000 description 4
- 208000014951 hematologic disease Diseases 0.000 description 4
- 208000018706 hematopoietic system disease Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 241001530209 Swertia Species 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 244000059800 Amomum compactum Species 0.000 description 2
- 235000016426 Amomum compactum Nutrition 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 241001113425 Iridaceae Species 0.000 description 2
- 241000758706 Piperaceae Species 0.000 description 2
- 241000501704 Swertia franchetiana Species 0.000 description 2
- 241000977602 Swertia mussotii Species 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 241000234299 Zingiberaceae Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- YKGYQYOQRGPFTO-UHFFFAOYSA-N bis(8-methylnonyl) hexanedioate Chemical compound CC(C)CCCCCCCOC(=O)CCCCC(=O)OCCCCCCCC(C)C YKGYQYOQRGPFTO-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 241000234599 Aconitum naviculare Species 0.000 description 1
- 241001586435 Aconitum tanguticum Species 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241001127714 Amomum Species 0.000 description 1
- 235000003826 Artemisia Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 241001529849 Dracocephalum Species 0.000 description 1
- 241001504825 Dracocephalum tanguticum Species 0.000 description 1
- 241001071804 Gentianaceae Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 240000007225 Limnophila aromatica Species 0.000 description 1
- 241001046985 Meconopsis impedita Species 0.000 description 1
- 241001046986 Meconopsis integrifolia Species 0.000 description 1
- 241001047058 Meconopsis punicea Species 0.000 description 1
- 241001047012 Meconopsis speciosa Species 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000395032 Swertia angustifolia Species 0.000 description 1
- 241000977603 Swertia chirayita Species 0.000 description 1
- 241000395019 Swertia ciliata Species 0.000 description 1
- 241001344977 Swertia cincta Species 0.000 description 1
- 241000096270 Swertia leducii Species 0.000 description 1
- 241000501703 Swertia tetraptera Species 0.000 description 1
- 240000008708 Vanda coerulea Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 235000009052 artemisia Nutrition 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 239000001209 crocus sativus l. Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008629 longdanxiegan Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000009527 percussion Methods 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a pharmaceutical composition, its preparation process and use, wherein the composition is prepared from pomegranate seed, safflower, long pepper, Cinnamomum cassia, cardamom, by a finite of weight ratio proportion, or from monkshood, Artemisinine, celery, cow-bezoar, potato, saffron, Chinese ephedra, and tabasheer. the composition is effective for treating various hepatitis.
Description
Technical field
The invention provides a kind of pharmaceutical composition and its production and use, specifically, is to be two kinds of pharmaceutical compositions of uniting use that raw material is used for the treatment of hepatitis with medical herbs, Chinese medicine, Tibetan medicine.
Background technology
Hepatitis is the infectious disease of commonly encountered diseases, multiple characteristic of disease, and especially at China's sickness rate height, all ages and classes all has this sick illness.Zhong Guo hepatitis B virus carriers reaches 1.5 hundred million people according to investigations, hepatitis B has been carried out many-sided research both at home and abroad in recent years, because hepatitis B virus is spherical, has double capsid, the resistance of environment is stronger to external world, and low temperature, drying, ultraviolet are all had toleration, not by 70% ethanol deactivation, still do not have effective Therapeutic Method at present, the medicine of developing the treatment hepatitis B has profound significance.Domestic treatment to the hepatitis disease does not at present have medicine targetedly, has only the medicine of auxiliary treatment, as: glucuronolatone, LONGDAN XIEGAN WAN etc., these medicines are difficult to satisfy the dissimilar hepatopathy that a variety of causes causes.On the Tibetanmedicine history, the prescription of treatment hepatopathy was just arranged before the centuries, such as " nine flavor Calculus Bovis balls ", " eight flavor DIDA balls " etc., through clinical practice, effect is undesirable, because of formulated, imperfections such as dosage form, drug effect reduces.
Summary of the invention
Technical problem to be solved of the present invention has provided a kind of pharmaceutical composition for the treatment of the drug combination of hepatitis, be the pharmaceutical composition of the drug combination made of raw material with medical herbs, Chinese medicine, Tibetan medicine specifically, the present invention also provides this preparation of drug combination method and purposes.
The invention provides a kind of pharmaceutical composition, it is to contain two kinds of pharmaceutical compositions of uniting use that therapeutic effect is arranged, and described two kinds of pharmaceutical compositions are respectively:
The medicament that composition I is made by following materials of weight proportions: 10～20 parts of Semen Granati, 10～20 parts on Flos Carthami, 5～10 parts of Fructus Piperis Longi, 5～10 parts of Cortex Cinnamomis, 1～2 part of Herba Meconopsis Horridulae, 10～20 parts of Fructus Amomi Rotunduss;
The medicament that composition I I is made by following materials of weight proportions: 10～20 parts of Aconitum carmichjaelii Debx.s, 10～20 parts of Herba meconopsis integrifoliae, 5～15 parts of Herba Swertiae bimaculataes, 1～2 part of Calculus Bovis, 10～20 parts of Herba Dracocephali tanguticis, 5～10 parts of Fructus Aristolochiaes, 1～2 part of Stigma Croci, 5～10 parts in Herba Ephedrae, 2～4 parts of Concretio silicea Bambusae seu schizostachyi.
Wherein, Fructus Piperis Longi derives from dry near maturation or the mature fruit cluster of Piperaceae (Piperaceae) plant Fructus Piperis Longi Piper longum L.; Thorniness yarn floss Artemisia has another name called Zuo Bameita, derives from: flower or the herb of bloodroot Herba Meconopsis Horridulae Meconopsis horridula Hook.f.et.Thoms; Fructus Amomi Rotundus, have another name called Fructus Amomi Rotundus, be the dry mature fruit of Zingiberaceae (Zingiberaceae) plant Fructus Amomi Rotundus Amomum kracanh Pirreex Gagnep. or amomum compactum Soland ex Maton Amomum compactum Soland ex.Maton, Aconitum carmichjaelii Debx. derives from the herb of ranunculaceae plant aconitum tanguticumStapf Aconitum tanguticum (Maxim.) Stapf. and ship helmet Aconitum carmichjaelii Debx. Aconitum naviculare (Bruhl.) Stapf.; Herba meconopsis integrifoliae comprises Scapus et Fructus Meconopsis Puniceae, entire leaf Herba meconopsis integrifoliae, five pulse conditions of ZANG-organs leaf Herba meconopsis integrifoliae, and wherein Scapus et Fructus Meconopsis Puniceae derives from bloodroot Scapus et Fructus Meconopsis Puniceae Meconopsis punicea Maxim, the western regions of the Yunnan Province Herba meconopsis integrifoliae Meconopsisimpedita Prain; Full edge Herba meconopsis integrifoliae derives from flower or the herb of the full edge Herba meconopsis integrifoliae of bloodroot Meconopsisintegrifolia (Maxim.) Franch. and circular cone Herba meconopsis integrifoliae Meconopsis paniculataPrain; Five pulse conditions of ZANG-organs leaf Herba meconopsis integrifoliae derives from the flower of bloodroot five pulse conditions of ZANG-organs leaf Herba meconopsis integrifoliae Meconopsis speciosa Prain; Herba Swertiae bimaculatae, have another name called DIDA, be gentianaceae plant Swertia mussotii Franch. Swertia mussotii Franch. and the herb that belongs to various plants together, also comprise Swertia franchetiana H.Smith Swertia franchetiana H.Smith., S.purpurasens. Wall Swertia ciliata (D.Don ex G.Don) B.L.Burtt., Herba Swertiae Mileensis Swertia mileensis T.N.H.etW.L.Ski., surrounded swertia herb Swertia Cincta Burk., Herba Swertiae bimaculatae Swertiaangustifolia Buch.-Ham ex D.Don var.pulchella (Buch-Ham) Burk., fork umbrella Herba Swertiae bimaculatae Swertia clichotoma L., Nepal Herba Swertiae bimaculatae Swertia chirata Ham., Swertia tetraptera Swertia tetraptetra Maxim., Yunnan Herba Swertiae bimaculatae Swertia yunanensisBurk.; Herba Dracocephali tangutici, have another name called dark blue orchid, know sheep so, derive from labiate Herba Dracocephali tangutici Dracocephalum tanguticum Maxim., U.S. leaf ultramarine Dracocephalum calophyllumHand.-Mazz. and belong to the aerial parts of various plants together.Stigma Croci has another name called Stigma Croci, is the dry stigma of Iridaceae (Iridaceae) plant Stigma Croci Crocus sativus L..
Further, it is by being made up of two kinds of pharmaceutical compositions of uniting use of therapeutic effect, and these two kinds of pharmaceutical compositions are respectively:
The medicament that composition I is made by following materials of weight proportions: 10～20 parts of Semen Granati, 10～20 parts on Flos Carthami, 5～10 parts of Fructus Piperis Longi, 5～10 parts of Cortex Cinnamomis, 1～2 part of Herba Meconopsis Horridulae, 10～20 parts of Fructus Amomi Rotunduss;
The medicament that composition I I is made by following materials of weight proportions: 10～20 parts of Aconitum carmichjaelii Debx.s, 10～20 parts of Herba meconopsis integrifoliae, 5～15 parts of Herba Swertiae bimaculataes, 1～2 part of Calculus Bovis, 10～20 parts of Herba Dracocephali tanguticis, 5～10 parts of Fructus Aristolochiaes, 1～2 part of Stigma Croci, 5～10 parts in Herba Ephedrae, 2～4 parts of Concretio silicea Bambusae seu schizostachyi.
Further, the medicament made by following materials of weight proportions of composition I: 10 parts of Semen Granati, 10 parts on Flos Carthami, 5 parts of Fructus Piperis Longi, 5 parts of Cortex Cinnamomis, 2 parts of Herba Meconopsis Horridulaes, 16 parts of Fructus Amomi Rotunduss;
The medicament that composition I I is made by following materials of weight proportions: 10 parts of Aconitum carmichjaelii Debx.s, 10 parts of Herba meconopsis integrifoliae, 10 parts of Herba Swertiae bimaculataes, 2 parts of Calculus Boviss, 16 parts of Herba Dracocephali tanguticis, 8 parts of Fructus Aristolochiaes, 2 parts of Stigma Crocis, 5 parts in Herba Ephedrae, 4 parts of Concretio silicea Bambusae seu schizostachyi.
Described medicament is powder, pill, tablet, capsule.
The present invention also provides two kinds of preparation of drug combination methods:
The preparation method of composition I is:
A, take by weighing raw material by weight ratio: 10～20 parts of Semen Granati, 10～20 parts on Flos Carthami, 5～10 parts of Fructus Piperis Longi, 5～10 parts of Cortex Cinnamomis, 1～2 part of Herba Meconopsis Horridulae, 10～20 parts of Fructus Amomi Rotunduss;
B, with above crude drug except that Herba Meconopsis Horridulae respectively at 100 ℃, being dried to moisture is below 8%, pulverizes, and sieves;
C, the powder after will sieving mix with Herba Meconopsis Horridulae, make dosage form pharmaceutically commonly used with acceptable accessories;
The preparation method of composition I I is:
A, take by weighing raw material by weight ratio: 10～20 parts of Aconitum carmichjaelii Debx.s, 10～20 parts of Herba meconopsis integrifoliae, 5～15 parts of Herba Swertiae bimaculataes, 1～2 part of Calculus Bovis, 10～20 parts of Herba Dracocephali tanguticis, 5～10 parts of Fructus Aristolochiaes, 1～2 part of Stigma Croci, 5～10 parts in Herba Ephedrae, 2～4 parts of Concretio silicea Bambusae seu schizostachyi;
B, with above crude drug respectively at 100 ℃, being dried to moisture is below 8%, pulverizes, and sieves;
C, the powder mixes after will sieving are made dosage form pharmaceutically commonly used with acceptable accessories.
The present invention also provides the described purposes of two kinds of each materials of weight proportions of pharmaceutical composition in the medicine of preparation treatment hepatitis of uniting use.
Further, provide the described purposes of two kinds of each materials of weight proportions of pharmaceutical composition in the medicine of preparation treatment hepatitis B of uniting use.
Wherein, described drug combination is meant simultaneously or successively uses two kinds of pharmaceutical compositions.Described drug combination is meant takes pharmaceutical composition I the morning, takes pharmaceutical composition II or use simultaneously afternoon.
Two of drug combination kinds of pharmaceutical composition material medicine prescriptions are based upon on the understanding basis of Tibetan medicine to the cause of disease of hepatitis in the pharmaceutical composition of the present invention, theory according to Tibetan's medicine and pharmacology uniqueness, particularly the Tibetan medicine and pharmacology great master arranges as just brightly thinking " basis of hepatopathy is at blood; it is shown liver; treating blood disorders and treat liver, can receive the effect for the treatment of both the principal and secondary aspects of a disease ".Pharmaceutical composition I raw material of the present invention is monarch drug with the Semen Granati, minister is with Flos Carthami, Herba Meconopsis Horridulae, is adjuvant drug with Cortex Cinnamomi, Fructus Piperis Longi, and Fructus Amomi Rotundus is a messenger drug, medicine of the present invention has the heat clearing away antiinflammatory, the treating blood disorders detoxifcation, nourishing stomach and spleen protects the liver jaundice eliminating, improve liver function, reducing changes ammonia, and large and small three sun are turned out cloudy, and is mainly used in the various dissimilar hepatitis of treatment.Pharmaceutical composition II raw material of the present invention is monarch drug with the Aconitum carmichjaelii Debx.; minister is a ministerial drug with Herba meconopsis integrifoliae, Herba Swertiae bimaculatae, Calculus Bovis, Herba Dracocephali tangutici; with Fructus Aristolochiae, Stigma Croci is adjuvant drug, and Herba Ephedrae, Concretio silicea Bambusae seu schizostachyi are messenger drug, and medicine of the present invention has heat clearing away antiinflammatory, treating blood disorders detoxifcation; nourishing stomach and spleen; protect the liver jaundice eliminating, improve liver function, transaminase lowering; large and small three sun are turned out cloudy, and are mainly used in the various dissimilar hepatitis of treatment.
The preparation technology of the present composition is simple, adopts direct crushing screening, compares pharmaceutical composition steady quality of the present invention with traditional water preparation, because the powder surface area is big, the active constituent content height easily disperses, rapid-action, effect relaxes, and is all effective in cure to dissimilar hepatitis.And the present invention adopts the drug combination of two kinds of pharmaceutical compositions, so-called drug combination is meant owing to multiple reason, the treatment disease needs two or more medicine to use simultaneously or successively sometimes, behind the drug combination, because physical and chemical reaction and interaction, can produce useful effect, reduce toxicity, make the bigger curative effect of medicine performance, and can reduce chemical sproof generation, show by clinical experiment, safety of medicine of the present invention, effectively, it is convenient to preserve, and provides a kind of new medication to select for clinical.
Obviously, according to foregoing of the present invention,,, can also make modification, replacement or the change of other various ways not breaking away under the above-mentioned basic fundamental thought of the present invention prerequisite according to the ordinary skill knowledge and the customary means of this area.
The specific embodiment of form is described in further detail foregoing of the present invention again by the following examples.But this should be interpreted as that the scope of the above-mentioned theme of the present invention only limits to following example.All technology that realizes based on foregoing of the present invention all belong to scope of the present invention.
The specific embodiment
The preparation of embodiment 1 pharmaceutical composition I of the present invention
A, take by weighing raw material by weight ratio: Semen Granati 10g, Flos Carthami 10g, Fructus Piperis Longi 5g, Cortex Cinnamomi 5g, Herba Meconopsis Horridulae 2g, Fructus Amomi Rotundus 16g;
B, with above crude drug except that Herba Meconopsis Horridulae respectively at 100 ℃, being dried to moisture is below 8%, pulverizes, and sieves;
C, the powder mixes after will sieving, encapsulated, every capsules 0.5g.
The preparation of embodiment 2 pharmaceutical composition I of the present invention
A, take by weighing raw material by weight ratio: Semen Granati 20g, Flos Carthami 15g, Fructus Piperis Longi 8g, Cortex Cinnamomi 10g, Herba Meconopsis Horridulae 2g, Fructus Amomi Rotundus 16g;
B, with above crude drug except that Herba Meconopsis Horridulae respectively at 100 ℃, being dried to moisture is below 8%, pulverizes, and sieves;
C, powder and Herba meconopsis integrifoliae powder mixes after will sieving, the system soft material is granulated, drying, granulate adds 1% magnesium stearate, tabletting, every heavy 0.5g.
The preparation of embodiment 3 pharmaceutical composition II of the present invention
A, take by weighing raw material by weight ratio: Aconitum carmichjaelii Debx. 10g, Herba meconopsis integrifoliae 10g, Herba Swertiae bimaculatae 10g, Calculus Bovis 2g, Herba Dracocephali tangutici 16g, Fructus Aristolochiae 8g, Stigma Croci 2g, Herba Ephedrae 5g, Concretio silicea Bambusae seu schizostachyi 4g;
B, with above crude drug respectively at 100 ℃, being dried to moisture is below 8%, pulverizes, and sieves;
C, the powder mixes after will sieving, encapsulated, every capsules 0.5g.
The preparation of embodiment 4 pharmaceutical composition II of the present invention
A, take by weighing raw material by weight ratio: Aconitum carmichjaelii Debx. 20g, Herba meconopsis integrifoliae 20g, Herba Swertiae bimaculatae 15g, Calculus Bovis 2g, Herba Dracocephali tangutici 16g, Fructus Aristolochiae 10g, Stigma Croci 2g, Herba Ephedrae 10g, Concretio silicea Bambusae seu schizostachyi 4g;
B, with above crude drug respectively at 100 ℃, being dried to moisture is below 8%, pulverizes, and sieves;
C, the powder mixes after will sieving, the system soft material is granulated, drying, granulate adds 1% magnesium stearate, tabletting, every heavy 0.5g.
Below prove beneficial effect of the present invention by clinical trial.
The clinical trial of test example 1 medicine of the present invention
To 100 routine hepatitis B clinical observation on the therapeutic effect, now observed result is reported as follows:
One, research method:
1, object of study:
Observe 130 outpatient service of routine the court and inpatients, be divided into treatment group and matched group at random.100 examples are organized in treatment, matched group 30 examples.All meet the chronic hepatitis diagnostic criteria of nineteen ninety-five parasitic disease association of Chinese Medical Association's infectious disease association formulation.
Two groups of patients' clinical data sees Table 1:
Table 1 treatment group and matched group clinical data
| The treatment group | Matched group |
| Case load (man, woman) 100 (47/53) | ?30(12/18) |
| The range of age (year) 21～63 | ?23～54 |
| Mean age 35.4 | ?32.6 |
| The course of disease 7 months～12 years | 6 months～10 years |
| Moderate example several 79 | ?25 |
| Severe example several 21 | ?5 |
| HBSAg (+) example several 61 | ?12 |
| HbeAg (+) example several 61 | ?18 |
| Anti-Hbe (+) example several 61 | ?12 |
Two groups of clinical datas are with statistical procedures, P＞0.05, and there was no significant difference has comparability.
2, Therapeutic Method:
Be subjected to the reagent thing: medicine of the present invention, oral, a twice-daily, each 1.0g～1.5g takes pharmaceutical composition I morning, takes pharmaceutical composition II evening.
Matched group: the DONGBAO JIAONANG that oral Chinese Dongbao of Tonghua pharmaceutcal corporation, Ltd produces.
3, observation item:
(1) every clinical symptoms, sign and side effect.
(2) detect liver function the end of each month, five indexes of hepatitis b, liver spleen B ultrasonic, routine blood test and kidney merit.
4, curative effect determinate standard:
Produce effects: clinical symptom disappearance, liver function recovery is normal.
Effectively: clinical symptom disappearance, the every index of liver function drop to the treatment before below 50%.
Invalid: clinical symptoms does not have improvement, liver function no change even increases the weight of.
Two, result:
The comparison of 1, treatment group and matched group clinical efficacy:
There were significant differences for statistical disposition P＜0.05 a liang group, and treatment group curative effect is better than matched group.
2, the variation of the symptom and sign before and after medicament capsule of the present invention and the matched group medication:
There were significant differences for treatment group and matched group, and symptom and sign are improved the aspect, and the treatment group is better than matched group.
3, Drug therapy hepatitis B of the present invention, viral index changes after treatment group and the matched group medication:
4, before treatment group and the matched group medication, the variation of ALT (serum alanine transaminase), TB (tubercule bacillus), A/G (albumins/globulins [ratio]):
5, side effect: during the medication, periodic monitoring routine blood test, blood glucose, renal function are not found side reaction.
Medicine of the present invention is taken by 100 routine hepatitis B patients, and clinical efficacy obviously is better than matched group, and the symptom Signs of hepatitis B patient is improved treatment group and matched group significant difference.HBSAg (hbs antigen) negative conversion rate 45.9%, HbeAg (hepatitis B e antigen) negative conversion rate 62.29%.Anti-HbeAg (hepatitis B e antibody) 81.97% is apparently higher than the matched group DONGBAO JIAONANG, the drug combination of proof pharmaceutical composition of the present invention has heat clearing away antiinflammatory, treating blood disorders detoxifcation, nourishing stomach and spleen protects the liver jaundice eliminating, improves liver function, transaminase lowering, improve the function of human body self immunity, and two kinds of pharmaceutical composition crude drug of the present invention source is abundant, treatment in accordance with local conditions, have no side effect, provide a kind of new medication to select for clinical.
Test example 2 typical case histories
Certain patient, first visit on July 11 in 1998, the upper right abdomen pain of patient is felt sick, was vomitted for 1 week, and upper right abdomen pain discomfort is weak, loss of appetite; Have a medical check-up: the bilateral yellow sclera, liver is 3～4cm under costal margin, there are tenderness and percussion pain in the hepatic region, B ultrasonic prompting hepatomegaly in the institute, laboratory examination serum bilirubin＞17.1umol/L, the urine bilirubin positive, look into two double, HbsAg (+), HbeAg (+), anti--Hbe (+), clinical diagnosis is an acute icterohepatitisshock, promptly obeys 2 courses of treatment of medicament capsule of the present invention (six months), various merging transference cures, serum bilirubin is normal, the urine bilirubin feminine gender, great three positive is turned out cloudy, the jaundice stripping, then take two courses of treatment and consolidate, not bounce-back.
By above-mentioned clinical testing data and typical analysis of medical record as can be known, it is scientific and reasonable that pharmaceutical composition of the present invention is united two kinds of pharmaceutical composition prescriptions of use, the use of uniting by these two kinds of pharmaceutical compositions, rapid-action, all effective to various hepatitis, safety of medicine of the present invention, effectively, it is convenient to preserve, and provides a kind of new medication to select for clinical.
Claims (6)
1, a kind of pharmaceutical composition for the treatment of hepatitis is characterized in that: it is that these two kinds of pharmaceutical compositions are respectively by two kinds of pharmaceutical compositions of uniting use that therapeutic effect is arranged:
The medicament that composition I is made by following materials of weight proportions: 10～20 parts of Semen Granati, 10～20 parts on Flos Carthami, 5～10 parts of Fructus Piperis Longi, 5～10 parts of Cortex Cinnamomis, 1～2 part of Herba Meconopsis Horridulae, 10～20 parts of Fructus Amomi Rotunduss;
The medicament that composition I I is made by following materials of weight proportions: 10～20 parts of Aconitum carmichjaelii Debx.s, 10～20 parts of Herba meconopsis integrifoliae, 5～15 parts of Herba Swertiae bimaculataes, 1～2 part of Calculus Bovis, 10～20 parts of Herba Dracocephali tanguticis, 5～10 parts of Fructus Aristolochiaes, 1～2 part of Stigma Croci, 5～10 parts in Herba Ephedrae, 2～4 parts of Concretio silicea Bambusae seu schizostachyi.
2, pharmaceutical composition according to claim 1 is characterized in that:
The medicament that composition I is made by following materials of weight proportions medicine: 10 parts of Semen Granati, 10 parts on Flos Carthami, 5 parts of Fructus Piperis Longi, 5 parts of Cortex Cinnamomis, 2 parts of Herba Meconopsis Horridulaes, 16 parts of Fructus Amomi Rotunduss;
The medicament that composition I I is made by following materials of weight proportions medicine: 10 parts of Aconitum carmichjaelii Debx.s, 10 parts of Herba meconopsis integrifoliae, 10 parts of Herba Swertiae bimaculataes, 2 parts of Calculus Boviss, 16 parts of Herba Dracocephali tanguticis, 8 parts of Fructus Aristolochiaes, 2 parts of Stigma Crocis, 5 parts in Herba Ephedrae, 4 parts of Concretio silicea Bambusae seu schizostachyi.
3, pharmaceutical composition according to claim 1 and 2 is characterized in that: described medicament is powder, pill, tablet or capsule.
4, the described preparation of drug combination method of claim 1 is characterized in that:
The preparation method of composition I is:
A, weighting raw materials by weight ratio: 10～20 parts of Semen Granati, 10～20 parts on Flos Carthami, 5～10 parts of Fructus Piperis Longi, 5～10 parts of Cortex Cinnamomis, 1～2 part of Herba Meconopsis Horridulae, 10～20 parts of Fructus Amomi Rotunduss;
B, with above crude drug except that Herba Meconopsis Horridulae respectively at 100 ℃, being dried to moisture is below 8%, pulverizes, and sieves;
C, the powder after will sieving mix with Herba Meconopsis Horridulae, make dosage form pharmaceutically commonly used with acceptable accessories;
The preparation method of composition I I is:
A, weighting raw materials by weight ratio: 10～20 parts of Aconitum carmichjaelii Debx.s, 10～20 parts of Herba meconopsis integrifoliae, 5～15 parts of Herba Swertiae bimaculataes, 1～2 part of Calculus Bovis, 10～20 parts of Herba Dracocephali tanguticis, 5～10 parts of Fructus Aristolochiaes, 1～2 part of Stigma Croci, 5～10 parts in Herba Ephedrae, 2～4 parts of Concretio silicea Bambusae seu schizostachyi;
B, with above crude drug respectively at 100 ℃, being dried to moisture is below 8%, pulverizes, and sieves;
C, the powder mixes after will sieving are made dosage form pharmaceutically commonly used with acceptable accessories.
5, the purposes of the described pharmaceutical composition of claim 1 in the medicine of preparation treatment hepatitis.
6, the purposes of the described pharmaceutical composition of claim 5 in the medicine of preparation treatment hepatitis B.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101041689A CN100528218C (en) | 2003-12-30 | 2003-12-30 | Pharmaceutical composition, its preparation process and usage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101041689A CN100528218C (en) | 2003-12-30 | 2003-12-30 | Pharmaceutical composition, its preparation process and usage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634159A CN1634159A (en) | 2005-07-06 |
| CN100528218C true CN100528218C (en) | 2009-08-19 |
Family
ID=34842973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101041689A Expired - Fee Related CN100528218C (en) | 2003-12-30 | 2003-12-30 | Pharmaceutical composition, its preparation process and usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100528218C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105497648A (en) * | 2016-01-22 | 2016-04-20 | 久美彭措 | Tibetan medicine for treating liver diseases of children |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1227752A (en) * | 1998-12-02 | 1999-09-08 | 曾庆湘 | Capsule for curing hepatitis B |
| CN1284360A (en) * | 2000-08-14 | 2001-02-21 | 久美彭措 | Tibeten medicine for treating hepatitis B and its preparation |
-
2003
- 2003-12-30 CN CNB2003101041689A patent/CN100528218C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1227752A (en) * | 1998-12-02 | 1999-09-08 | 曾庆湘 | Capsule for curing hepatitis B |
| CN1284360A (en) * | 2000-08-14 | 2001-02-21 | 久美彭措 | Tibeten medicine for treating hepatitis B and its preparation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1634159A (en) | 2005-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101708295A (en) | Chinese medicinal preparation for treating diabetes and preparation methods thereof | |
| CN101607059B (en) | Application of Chinese medicinal composition in preparing medicament for treating and preventing radiation injury | |
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN104784505A (en) | Dendrobium officinale healthcare product with auxiliary blood glucose reducing function and preparation method thereof | |
| CN101366913A (en) | Traditional Chinese medicine for treating male aciesis and preparation method thereof | |
| CN101732668B (en) | Preparation method of traditional Chinese medicine composition for treating urinary system infection | |
| CN101991744B (en) | Traditional Chinese medicine perfusion agent for treating milk cow endometritis | |
| CN106361830B (en) | Rhubarb powder and preparation method thereof | |
| CN100528218C (en) | Pharmaceutical composition, its preparation process and usage | |
| CN104940781A (en) | Traditional Tibetan medicine composition for treating nervous system diseases and preparation method thereof | |
| CN100381164C (en) | Medicine for treating radiation diseases | |
| CN1330359C (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN102652819B (en) | Fuyankang dispersible tablet and preparation method thereof | |
| CN104586932A (en) | Traditional Chinese medicine for increasing pregnancy rate of female animals and preparation process thereof | |
| CN104225425A (en) | Chinese herbal preparation for enhancing immunity, improving sleep and preventing cardio-cerebrovascular disease, and preparation method thereof | |
| CN1259095C (en) | Brain-quieting hypertension-treating medicine, and its preparing method and use | |
| CN102784364B (en) | Pure traditional Chinese medicine powder for preventing and treating chicken colibacillosis and preparation method of pure traditional Chinese medicine powder | |
| CN1517115A (en) | Chinese patent drug-Fuyan capsdule for treating chronic pelvic inflammation | |
| CN102579622A (en) | Chinese herbal preparation for treating haemophilusparasuis and preparation method thereof | |
| CN101849996A (en) | Three-drug adder-wort powder and preparation method thereof | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN1056071C (en) | Hepatitis virus inhibitor and prepn. method thereof | |
| CN100413529C (en) | Chinese medicinal composition for treating prostatitis and its preparation method | |
| CN1261110C (en) | Medicinal composition for treating common and infectious cold | |
| CN1943718B (en) | A Chinese traditional medicinal composition and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090819 Termination date: 20100201 |